Stocks
Editas Medicine (EDIT) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 1 571% | 2 206% | 1 786% | 4 249% | 3 636% | 3 170% | |||
| Changes by years, y/y, % | -336pp | +635pp | -420pp | +2 462pp | -613pp | +13.8% | |||
Editas Medicine. R&D/CAPEX, %
Editas Medicine. R&D/CAPEX, changes, pp
Editas Medicine (EDIT) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| R&D/CAPEX, % | 2 055% | 2 234% | 2 233% | 5 210% | 2 532% | 3 170% | ||
| Changes by years, y/y, % | +365pp | -4 674pp | -4 498pp | -3 123pp | +478pp | |||
| Changes by quarters, q/q, % | -6 278pp | +179pp | -1pp | +2 977pp | -2 677pp | |||
